These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316 [TBL] [Abstract][Full Text] [Related]
7. Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma. Capaldi IB; May AM; Schmitt-Graeff A; Follo M; Aumann K; Kayser G; Perazzo JC; Werner M; Fisch P Exp Mol Pathol; 2014 Aug; 97(1):57-65. PubMed ID: 24842316 [TBL] [Abstract][Full Text] [Related]
8. Significances of MYD88 Meng Q; Cao XX; Li J Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839 [TBL] [Abstract][Full Text] [Related]
9. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557 [TBL] [Abstract][Full Text] [Related]
13. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88 Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094 [TBL] [Abstract][Full Text] [Related]
14. Clinical application of genomics in Waldenström macroglobulinemia. Branagan AR; Lei M; Treon SP; Castillo JJ Leuk Lymphoma; 2021 Aug; 62(8):1805-1815. PubMed ID: 33569985 [TBL] [Abstract][Full Text] [Related]
15. MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia. Landgren O; Tageja N Leukemia; 2014 Sep; 28(9):1799-803. PubMed ID: 24573383 [TBL] [Abstract][Full Text] [Related]
16. Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis. Rossi D Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):113-8. PubMed ID: 25696843 [TBL] [Abstract][Full Text] [Related]
17. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing. Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512 [TBL] [Abstract][Full Text] [Related]